There has been significant interest, speculation and controversy about the potential health benefits of CBD.
The CBD-Intel Health hub provides access to our news briefings, data and research on developments related to the science behind CBD and health, from news of clinical trials to the latest rulings from key regulatory bodies such as the EU and the US FDA.
Interest in psychedelic drugs and treatments continues to grow, as evidenced by three major takeovers in Canada and the USA, two involving drug treatments developments and another offering a network of ketamine infusion treatment centres
Two North American entrepreneurs have put millions of dollars into exploring the treatment efficacy of psychedelics, based on personal experience of using them to help deal with their own mental health issues
CBD-Intel’s newly upgraded global regulatory tracker, updated every month, now offers a deeper analysis of each regulatory area.
Use the tabs at the top of the map to select a specific regulatory field and click on an individual country to bring up much more detail in the panel below, including links to legislation and CBD-Intel’s coverage of that market.
The key below the map indicates the level of regulation for the selected country and regulatory field based on our in-house analysis.
Medical cannabis advocates are keen to see if Sajid Javid’s appointment as UK health secretary means he will continue his work from 2018, when he helped change the law on medicinal cannabis prescriptions
France is lagging behind its neighbours on medical cannabis – the potential “green pig” of French agriculture – according to an author of a report which called for it to be legalised on health and finance grounds
Pain is a familiar part of everybody’s life, yet it remains a remarkably hard subject to study. It therefore is unsurprising that studies have come to differing conclusions on the use of cannabis and cannabinoids for pain relief
Scientific findings on the antimicrobial properties of cannabis – and in particular cannabinoids – have raised the question of whether they might play a role in combatting antibiotic-resistant bacteria such as MRSA
The CEO of one company targeted by the US Federal Trade Commission (FTC) in the first ever group of fines handed down by the government agency to CBD companies considers the event to be a David and Goliath victory of sorts
Renewed interest in financing of CBD and cannabis businesses could signal that investors are starting to be positive again about the future after companies seemingly weathered the worst of the storm in 2020
Efforts to supply the first CBD product to Brazil’s public healthcare system will have to wait a while longer – and there is some dispute between the institute preparing to produce it and the sponsors of a Congress bill
The Court of Justice of the European Union’s (CJEU) decision in the Kanavape case will have a tremendous impact on the CBD industry in the European Union (EU). However, the breadth of its impact is not yet fully realised. A number of things must happen beforehand and it may come down to further court rulings before a […]
The announcement is a full reversal from the EC on a position that many found surprising in the first place. It marks a stellar period for the regulation of CBD and other cannabinoids with major decisions in their favour at the Court of Justice of the European Union, United Nations and now the EC. The […]
Overall it seems the industry – particularly in Europe – is not expecting much from Black Friday sales. European companies appear to consider CBD products more as health products that are requirement purchases throughout the year as opposed to lifestyle products that might be purchased as a one off during a special sales event. The situation may be slightly different in […]
How important is the CJEU decision on the Kanavape case? The judgement in favour of CBD from the Courts of Justice of the European Union (CJEU) will almost certainly have significant long-term consequences for the CBD industry in Europe. It will likely influence the European Commission (EC)’s further assessment of the question of whether CBD is […]
Increasing numbers of CBD businesses are marketing products that chime with the wellness trend and now even Playboy is launching a line of CBD products in the US that promise physical and mental benefits
Maria Alejandra Estanga, our market analysts, presented the current status of the topicals market across the most important CBD markets during the Virtual Cannacosmo Health + Beauty Expo on 29st September.
A proposal to be voted on by Brazilian legislators in the coming weeks could legalise the growing of hemp for industrial purposes and cannabis for medical use
CBD is a relatively new ingredient on the health marketplace and interest in its potential benefits continues to grow and consumers are increasingly attracted to products that promise wellness benefits. It has attracted endorsement and investment from increasing numbers of celebrities and sports personalities. Names as big as will.i.am, Jay-Z and Beyoncé are among those investing or launching their own CBD brands and Gwyneth Paltrow is calling cannabis a “hero ingredient of the future”.
With so much rising interest in cannabinoids and the continuing growth of the wellness trend, it’s easy to see why business is booming for some but industry stakeholders need to stay on the right side of complex regulatory pathways for the lawful marketing of appropriate cannabis-derived products.
Stay on top of the ever-changing regulatory landscape with our CBD-Intel Health hub. It provides access to our news briefings, data and reports on developments related to the science behind CBD and health, from news of clinical trials to the latest rulings from the US FDA.
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.